# Sutro Biopharma Outlines Clinical and Preclinical ADC Data at World ADC Conference

- URL: https://stocks.freetheai.org/news/sutro-biopharma-outlines-clinical-and-preclinical-adc-data-at-world-adc-a463d5
- Published: 2026-10-12T12:00:00Z
- Category: company_news; sentiment: neutral; impact: low
- Symbols: [NASDAQ:STRO](https://stocks.freetheai.org/symbols/NASDAQ-STRO)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Sutro Biopharma, Inc. (NASDAQ:STRO) announced its participation at the 17th Annual World ADC Conference in San Diego, taking place from October 12 to October 15, 2026. The clinical-stage biotechnology firm is delivering multiple presentations, including a plenary talk on October 13 detailing early clinical safety and pharmacokinetic profiles for its antibody-drug conjugate candidate STRO-004. Company shares fell 6.85% to $14.27 following the announcement.

The conference serves as a platform for Sutro to highlight progress across its drug discovery pipeline and proprietary cell-free platform. In addition to clinical data on STRO-004, the company is sharing new preclinical insights regarding STRO-006 and its first wholly-owned dual-payload drug candidate, STRO-227. Sutro designs its next-generation antibody-drug conjugates to address complex cancer targets, improve therapeutic safety, and overcome resistance seen in single-payload treatments.

Investors and clinical observers will be tracking presentation details as sessions continue through October 15. Following the conference, Sutro plans to make the presented materials available in the scientific publications section of its website.

## Key points

- Sutro Biopharma, Inc. (NASDAQ:STRO) is presenting at the 17th Annual World ADC Conference in San Diego from October 12 to 15, 2026.
- The company is sharing early clinical safety and pharmacokinetic data for its STRO-004 candidate in an October 13 plenary session.
- Preclinical updates cover STRO-006 and STRO-227, the company's first wholly-owned dual-payload antibody-drug conjugate.
- Shares of Sutro Biopharma traded down 6.85% to $14.27 on Monday.

## Questions and answers

### What is Sutro Biopharma presenting at the World ADC Conference?

Sutro Biopharma is presenting early clinical safety data for STRO-004 alongside preclinical data for STRO-006 and STRO-227.

### When is the 17th Annual World ADC Conference taking place?

The conference takes place in San Diego from October 12 through October 15, 2026.

### Where can investors view Sutro Biopharma's conference materials?

Sutro Biopharma will upload the presentation content to the Scientific Publications section of its website after the event.